sellWeak cluster of 210b5-1 plan
David Charles Lubner sold $450k of ACLX
director at Arcellx, Inc.. 6,000 shares at an average of $75.00, traded Jan 20, 2026, filed Jan 20, 2026.
Warning score
10Value
$450k
6,000 shares
Holdings after
21,659
-22% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +15RoleDirector
- +17Trade size$450k at market
- +5Share of holdings soldSold 22% of holdings
- +8Cluster2 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001193125-26-017002, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jan 20, 2026 | MOption exercise Common Stock10b5-1 | +6,000 | $6.28 | $38k | 27,659 | Jan 20, 2026 |
| Jan 20, 2026 | SOpen-market sale Common Stock10b5-1 | -6,000 | $75.00 | $450k | 21,659 | Jan 20, 2026 |
| Jan 20, 2026 | MOption exercise Stock Option (right to buy)derivative10b5-1 | -6,000 | $0.00 | $0 | 59,405 | Jan 20, 2026 |
Related signals
Other insiders at Arcellx, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 38Weak | Arcellx, Inc. | Rami Elghandour SEE REMARKS | $10M 89,916 shares | -25% | |
| 45Moderate | Arcellx, Inc. | Michelle Gilson CHIEF FINANCIAL OFFICER | $1.3M 11,219 shares | -25% | |
| 39Weak | Arcellx, Inc. | Michelle Gilson CHIEF FINANCIAL OFFICER | $573k 8,384 shares | -16% | |
| 42Moderate | Arcellx, Inc. | Michelle Gilson CHIEF FINANCIAL OFFICER | $785k 11,291 shares | -17% | |
| 29Weak | Arcellx, Inc. | Christopher Heery CHIEF MEDICAL OFFICER | $403k 5,882 shares | -20% | |
| 31Weak | Arcellx, Inc. | Christopher Heery CHIEF MEDICAL OFFICER | $487k 7,437 shares | -20% | |
| 29Weak | Arcellx, Inc. | Christopher Heery CHIEF MEDICAL OFFICER | $393k 6,131 shares | -14% | |
| 20Weak | Arcellx, Inc. | Christopher Heery CHIEF MEDICAL OFFICER | $31k 340 shares | -54% | |
| 30Weak | Arcellx, Inc. | Michelle Gilson CHIEF FINANCIAL OFFICER | $488k 5,364 shares | -39% | |
| 38Weak | Arcellx, Inc. | Michelle Gilson CHIEF FINANCIAL OFFICER | $512k 5,946 shares | -30% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.